Rosabulin

Drug Profile

Rosabulin

Alternative Names: STA-5312

Latest Information Update: 09 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synta Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Oct 2008 Discontinued - Phase-I for Haematological malignancies in USA (IV)
  • 09 Oct 2008 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 30 Dec 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top